![]() | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral, Insufflated, Rectal |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H10IN |
Molar mass | 259.090 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
5-Iodo-2-aminoindane (5-IAI) is a drug which acts as a releasing agentofserotonin, norepinephrine, and dopamine.[2] It was developed in the 1990s by a team led by David E. NicholsatPurdue University.[3] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans.[3] Unlike related aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats, but is substantially less toxic than its corresponding amphetamine homologue pIA, with the damage observed barely reaching statistical significance.[2]
Sweden's public health agency suggested classifying 5-IAI as a hazardous substance, on September 25, 2019.[4]
| |
---|---|
Phenylalkyl- amines (other than cathinones) |
|
Cyclized phenyl- alkylamines |
|
Cathinones |
|
Tryptamines |
|
Chemical classes |
|